Data Readout

BioRestorative completes BRTX-100 enrollment, sets up 2027 spine trial readout

The sham-controlled Phase 2 trial in chronic lumbar disc disease finished enrolling 99 patients, with topline results expected in early 2027 and no validated cell therapy yet approved for the indication.

By AppliedXLJuly 13, 2026Trial NCT04042844

Executive Summary

BioRestorative Therapies finished enrolling its Phase 2 trial of an autologous stem cell therapy for chronic lumbar disc disease, moving the program toward a topline readout that will test whether a single injection beats a sham procedure on the primary efficacy measure.
No cell therapy has established a validated disease-modifying effect in this spine indication, so a positive result against a sham comparator would be the first read of its kind for this specific approach.
The sponsor's guided readout window sits after the trial's own registered primary completion date, a gap investors should track as the quarter approaches.
The program holds Fast Track designation and has discussed a BLA pathway with the FDA, positioning it for further development regardless of how the Phase 2 data land.

The trial

NCT04042844 is a randomized, double-blind, sham-controlled Phase 2 study testing a single dose of BRTX-100, an autologous hypoxically cultured mesenchymal stem cell therapy, in patients with chronic lumbar disc disease. The trial enrolled 99 patients across 15 U.S. sites, with enrollment completed in February 2026. The design uses a sham procedure as the comparator arm, a structure the company has described as consistent with registrational expectations in spine medicine. NCT04042844+1

The catalyst

BioRestorative said it intends to report topline results in early 2027, with a stated guidance window running from January 1 to March 31, 2027. That guidance, issued March 4, 2026, followed a positive FDA Type B meeting (a mid-development regulatory discussion) on the path to a Biologics License Application. The trial's own registered primary completion date is December 1, 2026, a date the sponsor has revised twice: from June 2023 to August 2024 in 2022, then from August 2024 to December 2026 in August 2025. The guided Q1 2027 readout window falls after that registered primary completion date, a gap that will need to close as database lock and blinded statistical analysis proceed. BioRestorative+1

The endpoint bar

Results have not yet posted to ClinicalTrials.gov. The trial's primary efficacy measure will be assessed against the sham control, the design element that sets the evidentiary threshold for any efficacy claim. BioRestorative has characterized blinded interim observations as reflecting a favorable safety profile and an efficacy signal, but the company has not disclosed the specific endpoint, effect size, or statistical result behind that characterization. NCT04042844+1

Competitive frame

No other industry-sponsored trial in chronic lumbar disc disease shares BRTX-100's cell therapy modality, and the broader indication landscape carries a single active trial, this one. That mechanistic isolation means the readout will not be benchmarked against a direct competitor result; the nearest context is the indication's own unmet-need profile, reinforced by the Fast Track designation the FDA granted the program in February 2025. A positive result that holds up under blinded analysis against the sham arm, and that persists in the confirmatory Phase 3 activity the company has said it is initiating, would be the type of evidence that changes how this mechanism is read in spine disease more broadly.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.